Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Treasury Shares (2021 - 2025)

Historic Treasury Shares for Cytek Biosciences (CTKB) over the last 5 years, with Q3 2025 value amounting to $3.3 million.

  • Cytek Biosciences' Treasury Shares fell 6441.39% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year decrease of 6441.39%. This contributed to the annual value of $4.0 million for FY2024, which is 3994.93% down from last year.
  • As of Q3 2025, Cytek Biosciences' Treasury Shares stood at $3.3 million, which was down 6441.39% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, Cytek Biosciences' Treasury Shares registered a high of $9.3 million during Q3 2024, and its lowest value of $104876.0 during Q4 2021.
  • Over the past 5 years, Cytek Biosciences' median Treasury Shares value was $2.6 million (recorded in 2023), while the average stood at $2.9 million.
  • Per our database at Business Quant, Cytek Biosciences' Treasury Shares surged by 101513.41% in 2022 and then plummeted by 8562.8% in 2024.
  • Cytek Biosciences' Treasury Shares (Quarter) stood at $104876.0 in 2021, then surged by 1015.13% to $1.2 million in 2022, then soared by 465.52% to $6.6 million in 2023, then tumbled by 39.95% to $4.0 million in 2024, then dropped by 17.1% to $3.3 million in 2025.
  • Its last three reported values are $3.3 million in Q3 2025, $3.3 million for Q2 2025, and $2.1 million during Q1 2025.